Access
To read this story in full you will need to login or make a payment (see right).
Opinion
Nature 461, 724-726 (8 October 2009) | doi:10.1038/461724a; Published online 7 October 2009
Open Innovation Challenges
-
Single-cell Analysis Platform
This Challenge is looking for novel approaches to analyzing changes at a single-cell level. This is...
-
Methods to Analyze Consumer Emotions
The Seeker is looking for methods to analyze consumer emotions. This Challenge requires only a writ...
nature jobs
Senior Lecturer / Lecturer in Filarial Parasitology
- LSTM
- Liverpool, United Kingdom
Senior Staff Scientist
- National Institute of Mental Health (NIMH)
- Bethesda, Maryland
An agenda for personalized medicine
Pauline C. Ng1, Sarah S. Murray2, Samuel Levy3 & J. Craig Venter1
Abstract
Pauline C. Ng, Sarah S. Murray, Samuel Levy and J. Craig Venter find differences in results from two direct-toconsumer genetics-testing companies. They therefore give nine recommendations to improve predictions.
Summary
- For seven diseases, 50% or less of the predictions of two companies agreed across five individuals
- Companies should communicate high risks better and test for drug response markers
- Community should study markers in all ethnicities and look at behaviour after tests
To read this story in full you will need to login or make a payment (see right).

